Vincent A Miller

List of Publications by Year in Descending Order

423 papers	18,210 citations	60 h-index	132 g-index
424 ext. papers	22,410 ext. citations	4.7 avg, IF	6.17 L-index

#	Paper	IF	Citations
423	Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. *European Urology Focus*, **2021**, 7, 1339-1346	5.1	20
422	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. *Npj Precision Oncology*, **2021**, 5, 21	9.8	2
421	Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT2): Challenges and Opportunities in Conducting an MD Anderson Randomized Study in Precision Oncology.. *Journal of Clinical Oncology*, **2021**, 39, 3140-3140	2.2	
420	Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 367.e1-367.e5	2.8	2
419	Clinical, histopathologic, and molecular profiles of PRKAR1A-inactivated melanocytic neoplasms. *Journal of the American Academy of Dermatology*, **2021**, 84, 1069-1071	4.5	1
418	Optimized EGFR Blockade Strategies in Addicted Gastroesophageal Adenocarcinomas. *Clinical Cancer Research*, **2021**, 27, 3126-3140	12.9	6
417	Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. *Translational Oncology*, **2021**, 14, 101184	4.9	2
416	Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation. *Case Reports in Oncology*, **2020**, 13, 456-461	1	1
415	Pan-Cancer Analysis of and Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. *JCO Precision Oncology*, **2020**, 4, 442-465	3.6	38
414	Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the Gene Have Durable Responses to ALK Kinase Inhibitors. *Lung Cancer: Targets and Therapy*, **2020**, 11, 33-39	2.9	1
413	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. *European Urology*, **2020**, 77, 548-556	10.2	19
412	Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions. *BJU International*, **2020**, 125, 739-746	5.6	7
411	Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).. *Journal of Clinical Oncology*, **2020**, 38, 9576-9576	2.2	0
410	PD-L1 expression, tumor mutational burden, and microsatellite instability status in 746 pancreas ductal adenocarcinomas.. *Journal of Clinical Oncology*, **2020**, 38, 757-757	2.2	0
409	Genomic alterations in colitis-associated cancers in comparison to those found in sporadic colorectal cancer and present in precancerous dysplasia.. *Journal of Clinical Oncology*, **2020**, 38, 191-191	2.2	1
408	Comprehensive genomic profiling in malignant myoepithelioma to suggest potential alternative diagnosis.. *Journal of Clinical Oncology*, **2020**, 38, e23530-e23530	2.2	
407	Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms. *JCO Precision Oncology*, **2020**, 4,	3.6	4

406	Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA. *Oncology*, **2020**, 98, 905-912	3.6	5
405	Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience. *Oncologist*, **2020**, 25, e1803-e1806	5.7	2
404	Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER Metastatic Breast Cancer. *Clinical Cancer Research*, **2020**, 26, 5974-5989	12.9	37
403	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. *Lancet Oncology, The*, **2020**, 21, 1589-1601	21.7	26
402	Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling. *Lung Cancer*, **2020**, 148, 69-78	5.9	14
401	Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. *Oncologist*, **2020**, 25, e198-e202	5.7	8
400	The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. *Oncologist*, **2020**, 25, e39-e47	5.7	8
399	A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples. *Journal of Molecular Diagnostics*, **2019**, 21, 1053-1066	5.1	72
398	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. *Cancer Cell*, **2019**, 36, 444-457.e7	24.3	69
397	Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion. *Journal of Thoracic Oncology*, **2019**, 14, e29-e30	8.9	3
396	Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. *JCO Precision Oncology*, **2019**, 3,	3.6	29
395	Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. *Cancer Immunology Research*, **2019**, 7, 866-873	12.5	13
394	Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. *Nature Medicine*, **2019**, 25, 744-750	50.5	240
393	Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. *Gastroenterology*, **2019**, 156, 2242-2253.e4	13.3	117
392	On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. *Clinical Cancer Research*, **2019**, 25, 3341-3351	12.9	51
391	Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. *Leukemia*, **2019**, 33, 390-402	10.7	30
390	Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. *Oncologist*, **2019**, 24, 219-228	5.7	17
389	Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors. *European Urology Focus*, **2019**, 5, 748-755	5.1	11

388	-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. *Oncologist*, **2019**, 24, 1462-1468	5.7	6
387	Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy. *Journal of Gastrointestinal Oncology*, **2019**, 10, 831-840	2.8	18
386	Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. *Journal of Clinical Investigation* , **2019**, 129, 4276-4289	15.9	64
385	Comprehensive Genomic Profiling of 104 Rare Histiocytic and Dendritic Cell Neoplasms Reveals Shared and Distinct Targetable Genomic Alterations. *Blood*, **2019**, 134, 2541-2541	2.2	2
384	Immunotherapy predictive biomarkers in metastatic breast cancer (MBC).. *Journal of Clinical Oncology*, **2019**, 37, 1023-1023	2.2	2
383	Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).. *Journal of Clinical Oncology*, **2019**, 37, 4087-4087	2.2	24
382	Adenocarcinoma (ACB), urothelial carcinoma (UCB) and squamous cell carcinoma (SCCB) of the bladder: A Comprehensive Genomic Profiling (CGP) Study.. *Journal of Clinical Oncology*, **2019**, 37, 4533-4533	2.2	1
381	Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development.. *Journal of Clinical Oncology*, **2019**, 37, 4581-4581	2.2	4
380	Metastatic penile (mPSCC), uterine cervical (mCSCC), and skin (mSSCC) squamous cell carcinomas: A comparative genomic profiling (CGP) study.. *Journal of Clinical Oncology*, **2019**, 37, 4585-4585	2.2	0
379	Characterization of 648 non-small cell lung cancer (NSCLC) cases with 28 unique HER2 exon 20 insertions.. *Journal of Clinical Oncology*, **2019**, 37, 9063-9063	2.2	3
378	MSI-H testing via hybrid capture based NGS sequencing of liquid biopsy samples.. *Journal of Clinical Oncology*, **2019**, 37, 504-504	2.2	2
377	Penile and uterine cervical squamous cell carcinomas: A comparative genomic profiling study.. *Journal of Clinical Oncology*, **2019**, 37, 514-514	2.2	2
376	Genomic features of metastatic testicular sex cord stromal tumors.. *Journal of Clinical Oncology*, **2019**, 37, 532-532	2.2	1
375	MHC-1 genotype as a predictor of response to immunotherapy.. *Journal of Clinical Oncology*, **2019**, 37, 149-149	2.2	1
374	Tumor mutational burden (TMB) may be a promising predictive biomarker of response to PD-1/PD-L1 targeting in MSI-H colorectal cancer.. *Journal of Clinical Oncology*, **2019**, 37, 43-43	2.2	2
373	Anal melanoma: A comparative comprehensive genomic profiling study.. *Journal of Clinical Oncology*, **2019**, 37, 551-551	2.2	
372	FGFR2-altered gastroesophageal adenocarcinomas (GEA) are a rare clinicopathologic entity with a distinct genomic landscape.. *Journal of Clinical Oncology*, **2019**, 37, 72-72	2.2	
371	KRAS amplification and mutation are independent events in gastroesophageal adenocarcinomas (GEA).. *Journal of Clinical Oncology*, **2019**, 37, 70-70	2.2	

370	Analysis of EGFR mutant upper tract and bladder urothelial carcinoma (UC) reveals distinct mutational landscape.. *Journal of Clinical Oncology*, **2019**, 37, 416-416	2.2	
369	Ductal and acinar carcinomas of the prostate: A comparative comprehensive genomic profiling study.. *Journal of Clinical Oncology*, **2019**, 37, 271-271	2.2	
368	Genomic findings in adenocarcinoma of the urinary bladder.. *Journal of Clinical Oncology*, **2019**, 37, 132-132	2.2	
367	Malignant pheochromocytoma: A comprehensive genomic profiling study.. *Journal of Clinical Oncology*, **2019**, 37, 508-508	2.2	0
366	Analysis of HER2 mutant bladder urothelial carcinomas reveals unique mutational signature.. *Journal of Clinical Oncology*, **2019**, 37, 460-460	2.2	
365	Accelerating advanced precision medicine through a harmonized data exchange platform and research consortium (PMEC).. *Journal of Clinical Oncology*, **2019**, 37, 6557-6557	2.2	
364	Analysis of EGFR mutant urothelial carcinoma (UC) reveals distinct mutational landscape.. *Journal of Clinical Oncology*, **2019**, 37, 4545-4545	2.2	
363	Malignant pheochromocytoma (MP): A comprehensive genomic profiling (CGP) study.. *Journal of Clinical Oncology*, **2019**, 37, 4584-4584	2.2	
362	RAS-amplified colorectal cancers: Microsatellite stability status, RAS/BRAF mutations, and prediction of anti-EGFR resistance.. *Journal of Clinical Oncology*, **2019**, 37, 3533-3533	2.2	
361	KRAS amplification and mutation as independent events in gastroesophageal adenocarcinomas (GEA).. *Journal of Clinical Oncology*, **2019**, 37, e15565-e15565	2.2	
360	Extra-mammary Paget□ disease (EMPD) of the skin: A comprehensive genomic profiling (CGP) study.. *Journal of Clinical Oncology*, **2019**, 37, 9591-9591	2.2	
359	FGFR2: A pan-genomic target.. *Journal of Clinical Oncology*, **2019**, 37, 3099-3099	2.2	
358	Anal melanoma: A comparative comprehensive genomic profiling study.. *Journal of Clinical Oncology*, **2019**, 37, 9566-9566	2.2	
357	Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing. *Oncologist*, **2019**, 24, 657-663	5.7	1
356	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. *Oncologist*, **2019**, 24, 1340-1347	5.7	43
355	Pan-Cancer Analysis of Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype. *Oncologist*, **2019**, 24, 1526-1533	5.7	23
354	MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel R1004G Mutation. *Oncologist*, **2019**, 24, 1305-1308	5.7	1
353	Genomic Landscape of Adult and Pediatric -Like B-Lymphoblastic Leukemia Using Parallel DNA and RNA Sequencing. *Oncologist*, **2019**, 24, 372-374	5.7	2

352	The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. *Clinical Cancer Research*, **2019**, 25, 5961-5971	12.9	58
351	Atypical Mutations in Metastatic Colorectal Cancer.. *JCO Precision Oncology*, **2019**, 3, 1-11	3.6	
350	Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. *Cancer*, **2019**, 125, 1185-1199	6.4	27
349	Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling. *Journal of Thoracic Oncology*, **2019**, 14, 54-62	8.9	33
348	Combined Blockade of Activating Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. *Clinical Cancer Research*, **2019**, 25, 277-289	12.9	35
347	Comprehensive genetic alteration profiling in primary and recurrent glioblastoma. *Journal of Neuro-Oncology*, **2019**, 142, 111-118	4.8	17
346	Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2019**, 14, 255-264	8.9	28
345	Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. *British Journal of Cancer*, **2018**, 118, 1238-1242	8.7	25
344	Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. *Blood*, **2018**, 131, 2501-2505	2.2	32
343	Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. *Clinical Cancer Research*, **2018**, 24, 1881-1890	12.9	36
342	C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K Inhibitors. *Clinical Cancer Research*, **2018**, 24, 1426-1435	12.9	17
341	BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. *Clinical Breast Cancer*, **2018**, 18, 184-188	3	25
340	Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. *Oncologist*, **2018**, 23, 776-781	5.7	7
339	Comprehensive Genomic Profiling of Renal Cell Carcinoma at Initial Diagnosis and Putative Local Recurrence. *European Urology Focus*, **2018**, 4, 267-269	5.1	1
338	Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-N848 K mutation. *Lung Cancer*, **2018**, 124, 86-89	5.9	
337	Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden. *Lung Cancer: Targets and Therapy*, **2018**, 9, 45-47	2.9	9
336	Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. *Journal of Thoracic Oncology*, **2018**, 13, 1312-1323	8.9	65
335	Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. *JAMA Oncology*, **2018**, 4, 1237-1244	13.4	149

334	A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. *PLoS Computational Biology*, **2018**, 14, e1005965	5	109
333	Primary pulmonary sarcomas (PSRC): A comprehensive genomic profiling (CGP) study.. *Journal of Clinical Oncology*, **2018**, 36, 11553-11553	2.2	1
332	Frequency of genomic biomarkers of response to immunotherapy in sarcoma.. *Journal of Clinical Oncology*, **2018**, 36, 11579-11579	2.2	1
331	WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies.. *Journal of Clinical Oncology*, **2018**, 36, 12011-12011	2.2	7
330	PBRM1 mutation and immunotherapy efficacy: A comprehensive genomic profiling (CGP) assessment.. *Journal of Clinical Oncology*, **2018**, 36, 12091-12091	2.2	3
329	MSI-high and MSI-stable colorectal carcinomas (CRC): A comprehensive genomic profiling (CGP) study.. *Journal of Clinical Oncology*, **2018**, 36, 3574-3574	2.2	2
328	Comprehensive genomic characterization of chemotherapy-resistant testicular germ cell tumors (TGCT).. *Journal of Clinical Oncology*, **2018**, 36, 4555-4555	2.2	1
327	PBRM1 genomic alterations in mesothelioma: Potential predictor of immunotherapy efficacy.. *Journal of Clinical Oncology*, **2018**, 36, 8562-8562	2.2	1
326	Characterization of 1,233 NSCLCs with non-del19/L858R EGFR mutations (EGFRm) using comprehensive genomic profiling (CGP).. *Journal of Clinical Oncology*, **2018**, 36, 9040-9040	2.2	3
325	Comprehensive genomic profiling to identify recurrent kinase fusions in pancreatic ductal adenocarcinoma.. *Journal of Clinical Oncology*, **2018**, 36, 292-292	2.2	1
324	Genomic alterations (GA) predicted to confer lack of benefit from trastuzumab in advanced esophagogastric cancers (EGC): Analysis of 527 HER2-amplified (HER2amp) cases.. *Journal of Clinical Oncology*, **2018**, 36, 44-44	2.2	4
323	Comprehensive genomic profiling of ctDNA in patients with colon cancer and its fidelity to the genomics of the tumor biopsy.. *Journal of Clinical Oncology*, **2018**, 36, 569-569	2.2	4
322	Difference of genomic signatures and opportunities for targeted and immunotherapies in castrate resistant TMPRSS2:ERG fusion positive and TMPRSS2:ERG wild type refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).. *Journal of Clinical Oncology*, **2018**, 36, 348-348	2.2	1
321	Correlation of circulating tumor DNA (ctDNA) assessment with tissue-based comprehensive genomic profiling (CGP) in metastatic urothelial cancer (mUC).. *Journal of Clinical Oncology*, **2018**, 36, 453-453	2.2	2
320	Refractory testicular pure seminoma (PS) and non-seminomatous(NS) germ cell tumors (GCT): A comprehensive genomic profiling (CGP) study.. *Journal of Clinical Oncology*, **2018**, 36, 565-565	2.2	1
319	Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling. *Oncotarget*, **2018**, 9, 26417-26430	3.3	10
318	Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancer. *Oncotarget*, **2018**, 9, 33995-34008	3.3	5
317	Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors. *Oncotarget*, **2018**, 9, 35809-35812	3.3	22

316	Comparison of tumor mutational burden (TMB) in PBRM1/BAP1-based subsets of advanced renal cell carcinoma (aRCC).. *Journal of Clinical Oncology*, **2018**, 36, 634-634	2.2	1
315	Comprehensive genomic profiling (CGP) in KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC).. *Journal of Clinical Oncology*, **2018**, 36, 271-271	2.2	
314	Carcinomas of the renal medulla: A comprehensive genomic profiling (CGP) study.. *Journal of Clinical Oncology*, **2018**, 36, 640-640	2.2	
313	Comparative genomic profiling (CGP) of refractory/metastatic penile (mPSCC) and non-penile cutaneous squamous cell carcinoma (mCSCC).. *Journal of Clinical Oncology*, **2018**, 36, 552-552	2.2	1
312	Utility of comprehensive genomic profiling (CGP) to distinguish neoplasms pathologically diagnosed as PanNETs and PanNECs and identify potentially actionable genomic alterations (GA).. *Journal of Clinical Oncology*, **2018**, 36, 274-274	2.2	
311	Analysis of over 100,000 patients with cancer for CD274 (PD-L1) amplification: Implications for treatment with immune checkpoint blockade.. *Journal of Clinical Oncology*, **2018**, 36, 47-47	2.2	0
310	Analysis of DNA damage response (DDR) genes and tumor mutational burden (TMB) across 17,486 carcinomas of the tubular GI tract: Implications for therapy.. *Journal of Clinical Oncology*, **2018**, 36, 43-43	2.2	
309	Choroid plexus tumors of the central nervous system: Searching for therapy targets with comprehensive genomic profiling.. *Journal of Clinical Oncology*, **2018**, 36, e14084-e14084	2.2	
308	PD-L1 genomic alterations (GA) in solid tumors and hematologic malignancies: A comprehensive genomic profiling (CGP) study.. *Journal of Clinical Oncology*, **2018**, 36, 12092-12092	2.2	
307	Co-existing alterations in cell-cycle pathway genes and impact on benefit from trastuzumab in advanced esophagogastric cancers (EGC): Analysis of 527 Her2-amplified cases.. *Journal of Clinical Oncology*, **2018**, 36, 4063-4063	2.2	
306	FGFR3 Driven Metastatic Urothelial Carcinoma of the Urinary Bladder (mUCB): A Comprehensive Genomic Profiling Study.. *Journal of Clinical Oncology*, **2018**, 36, 4531-4531	2.2	
305	Genomic subtypes of angiosarcoma: A comprehensive genomic profiling (CGP) study.. *Journal of Clinical Oncology*, **2018**, 36, 11576-11576	2.2	
304	Clinicopathologic characteristics and molecular features of BRG1-deficient non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2018**, 36, 12083-12083	2.2	
303	Carcinomas of the renal medulla: A comprehensive genomic profiling (CGP) study.. *Journal of Clinical Oncology*, **2018**, 36, e16586-e16586	2.2	
302	Comprehensive genomic profiling of lung cancer cytologic specimens obtained by guided fine-needle aspirate biopsies.. *Journal of Clinical Oncology*, **2018**, 36, e21002-e21002	2.2	
301	Comprehensive genomic profiling of metastatic cutaneous adnexal carcinomas to reveal multiple routes to targeted and immunotherapies.. *Journal of Clinical Oncology*, **2018**, 36, 9587-9587	2.2	
300	Identifying the prognostic significance of genomic alterations in a real-world, EHR-derived clinico-genomic database (CGDB).. *Journal of Clinical Oncology*, **2018**, 36, e24319-e24319	2.2	
299	Comprehensive genomic profiling of acral and mucosal melanomas to support clinical decision making.. *Journal of Clinical Oncology*, **2018**, 36, e21629-e21629	2.2	

298	Primary sarcomas of the urinary bladder: A comprehensive genomic profiling (CGP) study.. *Journal of Clinical Oncology*, **2018**, 36, e16530-e16530	2.2	
297	Investigation of profile-related evidence determining individualized cancer therapy (I-PREDICT) in heavily pre-treated patients: A role for combinatorial precision cancer therapy.. *Journal of Clinical Oncology*, **2018**, 36, 2531-2531	2.2	
296	Comprehensive genomic profiling of brain tumors to provide targeted therapy options and diagnostic certainty for oligodendrogliomas.. *Journal of Clinical Oncology*, **2018**, 36, 2039-2039	2.2	
295	Landscape of kinase rearrangements (kRE) detected in circulating tumor DNA (ctDNA).. *Journal of Clinical Oncology*, **2018**, 36, 12041-12041	2.2	
294	Differences in genomic signatures and opportunities for targeted and immunotherapy treatment between castrate-resistant TMPRSS2:ERG fusion-positive and -negative refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).. *Journal of Clinical Oncology*, **2018**, 36, 5061-5061	2.2	
293	Prevalence of microsatellite instability and association with pembrolizumab (P) usage in a real-world clinico-genomic database.. *Journal of Clinical Oncology*, **2018**, 36, e15072-e15072	2.2	
292	Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. *European Urology*, **2018**, 73, 71-78	10.2	54
291	Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies. *OncoImmunology*, **2018**, 7, e1404217	7.2	30
290	in Lung Cancers: Analysis of Patient Cases Reveals Recurrent Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. *JCO Precision Oncology*, **2018**, 2,	3.6	8
289	Genomic Landscape of Appendiceal Neoplasms. *JCO Precision Oncology*, **2018**, 2,	3.6	5
288	Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study. *JCO Precision Oncology*, **2018**, 2,	3.6	8
287	Durable Clinical Response to Larotrectinib in an Adolescent Patient With an Undifferentiated Sarcoma Harboring an - Fusion. *JCO Precision Oncology*, **2018**, 2,	3.6	1
286	Genomic Profiling of T-Cell Neoplasms Reveals Frequent and Mutations With Clonal Evasion From Targeted Therapies. *JCO Precision Oncology*, **2018**, 2018,	3.6	14
285	Complete Response to a Fibroblast Growth Factor Receptor Inhibitor in a Patient With Head and Neck Squamous Cell Carcinoma Harboring Amplifications. *JCO Precision Oncology*, **2018**, 2,	3.6	7
284	Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. *Journal of Gastrointestinal Oncology*, **2018**, 9, 610-617	2.8	131
283	Large-Cell Neuroendocrine Carcinoma of the Lung: A Focused Analysis of Alterations and Case Report of a Non-V600-Mutated Tumor Responding to Targeted Therapy.. *JCO Precision Oncology*, **2018**, 2, 1-12	3.6	2
282	Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. *Journal of Clinical Oncology*, **2018**, 36, 1199-1206	2.2	155
281	Approach to evaluating tumor mutational burden in routine clinical practice. *Translational Lung Cancer Research*, **2018**, 7, 678-681	4.4	13

280	Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors. *Journal of Hematology and Oncology*, **2018**, 11, 129	22.4	17
279	Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. *Journal of Thoracic Oncology*, **2018**, 13, 1560-1568	8.9	75
278	Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. *Journal of Molecular Diagnostics*, **2018**, 20, 686-702	5.1	103
277	Identification of NTRK fusions in pediatric mesenchymal tumors. *Pediatric Blood and Cancer*, **2017**, 64, e26433	3	71
276	RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients. *Clinical Lung Cancer*, **2017**, 18, e223-e232	4.9	21
275	Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion. *Clinical Lung Cancer*, **2017**, 18, e219-e222	4.9	9
274	Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. *Cancer Research*, **2017**, 77, 509-519	10.1	60
273	ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2017**, 12, 872-877	8.9	63
272	Comprehensive genomic profiling of malignant phyllodes tumors of the breast. *Breast Cancer Research and Treatment*, **2017**, 162, 597-602	4.4	31
271	Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. *Oncologist*, **2017**, 22, 255-263	5.7	42
270	An Acquired Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. *Cancer Discovery*, **2017**, 7, 575-585	24.4	66
269	High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis. *Cancer Research*, **2017**, 77, 2464-2475	10.1	71
268	CD74-ROS1 Fusion in NSCLC Detected by Hybrid Capture-Based Tissue Genomic Profiling and ctDNA Assays. *Journal of Thoracic Oncology*, **2017**, 12, e19-e20	8.9	5
267	Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. *Genome Medicine*, **2017**, 9, 34	14.4	1509
266	Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. *Journal of Thoracic Oncology*, **2017**, 12, e155-e157	8.9	5
265	Detection of an Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA. *Oncologist*, **2017**, 22, 774-779	5.7	14
264	A Case of Metastatic Atypical Neuroendocrine Tumor with Translocation and Diffuse Brain Metastases. *Oncologist*, **2017**, 22, 768-773	5.7	25
263	Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib. *Leukemia and Lymphoma*, **2017**, 58, 2969-2972	1.9	11

262	Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an variant. *Journal of Physical Education and Sports Management*, **2017**, 3,	2.8	17
261	Genomic Profiling of Small-Bowel Adenocarcinoma. *JAMA Oncology*, **2017**, 3, 1546-1553	13.4	101
260	Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common Alteration. *Oncologist*, **2017**, 22, 416-421	5.7	33
259	Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. *Journal of Thoracic Oncology*, **2017**, 12, 932-942	8.9	85
258	HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib. *Journal of Thoracic Oncology*, **2017**, 12, 446-457	8.9	59
257	Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer. *Clinical Lung Cancer*, **2017**, 18, e211-e213	4.9	7
256	A case of advanced infantile myofibromatosis harboring a novel MYH10-RET fusion. *Pediatric Blood and Cancer*, **2017**, 64, e26377	3	5
255	General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study. *Human Pathology*, **2017**, 70, 84-91	3.7	13
254	Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy. *Cancer*, **2017**, 123, 3628-3637	6.4	30
253	Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center. *Theranostics*, **2017**, 7, 2914-2923	12.1	20
252	Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden **2017**, 5, 75		42
251	Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2-Targeted Therapy.. *JCO Precision Oncology*, **2017**, 1, 1-9	3.6	
250	Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. *JCO Precision Oncology*, **2017**, 1,	3.6	14
249	TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies. *JCO Precision Oncology*, **2017**, 2017,	3.6	6
248	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. *Molecular Cancer Therapeutics*, **2017**, 16, 2598-2608	6.1	1183
247	Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. *Oncologist*, **2017**, 22, 1478-1490	5.7	126
246	Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. *Lung Cancer*, **2017**, 113, 51-58	5.9	12
245	Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. *Lung Cancer*, **2017**, 111, 61-64	5.9	29

244	Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus. *Cell*, **2017**, 171, 982-986	56.2	12
243	Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping. *Journal of Thoracic Oncology*, **2017**, 12, e89-e90	8.9	25
242	Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options. *Oncologist*, **2017**, 22, 834-842	5.7	26
241	Unique genomic features in adolescent and young adult, as compared to older adult, non-Hodgkin lymphoma and potential therapeutic targets. *British Journal of Haematology*, **2017**, 178, 640-642	4.5	2
240	Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma. *Head and Neck*, **2017**, 39, E15-E19	4.2	9
239	Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping. *Journal of Thoracic Oncology*, **2017**, 12, 137-140	8.9	72
238	Inactivation of Capicua drives cancer metastasis. *Nature Genetics*, **2017**, 49, 87-96	36.3	92
237	Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. *JCI Insight*, **2017**, 2, e89473	9.9	48
236	BRAF: An emerging target for triple-negative breast cancer.. *Journal of Clinical Oncology*, **2017**, 35, 1099-1099	2.2	5
235	Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma.. *Journal of Clinical Oncology*, **2017**, 35, 11001-11001	2.2	20
234	Genomic profiling of squamous malignancies across anatomic sites.. *Journal of Clinical Oncology*, **2017**, 35, 11512-11512	2.2	2
233	Identification of novel fumarate hydratase gene alterations in prostate cancer.. *Journal of Clinical Oncology*, **2017**, 35, 11585-11585	2.2	2
232	Molecular landscape of BRAF mutations in large cell neuroendocrine carcinoma of lung: An analysis of BRAF mutations and a case report of a BRAF non-V600E mutated tumor responding to targeted therapy.. *Journal of Clinical Oncology*, **2017**, 35, 11621-11621	2.2	2
231	Personalized, molecularly matched combination therapies for treatment-na.. *Journal of Clinical Oncology*, **2017**, 35, 2512-2512	2.2	9
230	Development and validation of a real-world clinicogenomic database.. *Journal of Clinical Oncology*, **2017**, 35, 2514-2514	2.2	5
229	Targeted therapy for HER2 driven colorectal cancer.. *Journal of Clinical Oncology*, **2017**, 35, 3583-3583	2.2	3
228	Precision medicine for gallbladder cancer using somatic copy number amplifications (SCNA) and DNA repair pathway gene alterations.. *Journal of Clinical Oncology*, **2017**, 35, 4076-4076	2.2	4
227	Comprehensive genomic profiling (CGP) of advanced papillary renal cell carcinoma (PRCC) to reveal distinctions from TCGA dataset.. *Journal of Clinical Oncology*, **2017**, 35, 4517-4517	2.2	3

226	Comprehensive genomic profiling of parathyroid carcinoma.. *Journal of Clinical Oncology*, **2017**, 35, 6088-6088	2.2	1
225	Estimated cost of anticancer therapy directed by comprehensive genomic profiling (CGP) in a single-center study.. *Journal of Clinical Oncology*, **2017**, 35, 6605-6605	2.2	3
224	Genomic alterations (GA) and tumor mutational burden (TMB) in large cell neuroendocrine carcinoma of lung (L-LCNEC) as compared to small cell lung carcinoma (SCLC) as assessed via comprehensive genomic profiling (CGP).. *Journal of Clinical Oncology*, **2017**, 35, 8517-8517	2.2	10
223	Association of ALK resistance mutations by EML4-ALK variant (v3 vs. non-v3) in ALK+ non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2017**, 35, 9010-9010	2.2	11
222	Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2017**, 35, 9025-9025	2.2	1
221	BRAF fusions in clinically advanced non-small cell lung cancer: An emerging target for anti-BRAF therapies.. *Journal of Clinical Oncology*, **2017**, 35, 9072-9072	2.2	6
220	Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes.. *Journal of Clinical Oncology*, **2017**, 35, 9536-9536	2.2	13
219	Comprehensive genomic profiling to identify tumor mutational burden (TMB) as an independent predictor of response to immunotherapy in diverse cancers.. *Journal of Clinical Oncology*, **2017**, 35, e14508-e14508	2.2	2
218	Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced cancers of the GI tract and anus.. *Journal of Clinical Oncology*, **2017**, 35, 618-618	2.2	1
217	Comprehensive genomic profiling of relapsed and refractory small cell neuroendocrine carcinoma of the urinary bladder.. *Journal of Clinical Oncology*, **2017**, 35, 350-350	2.2	2
216	Genomic profiling of nephrectomy and metastatic sites in patients with advanced clear cell renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2017**, 35, 513-513	2.2	1
215	Comprehensive genomic sequencing of prostate sarcomatoid carcinoma tumors identifies differences in genomic alterations compared to prostate adenocarcinoma tumors.. *Journal of Clinical Oncology*, **2017**, 35, 226-226	2.2	1
214	Comprehensive genomic profiling (CGP) of esophageal and tubular GI tumors to identify frequencies of ErbB family member amplification with therapeutic implications.. *Journal of Clinical Oncology*, **2017**, 35, 8-8	2.2	
213	Comprehensive genomic sequencing of appendiceal cancer tumors to identify different genomic alterations by subtype, novel treatment opportunities, and improved outcomes.. *Journal of Clinical Oncology*, **2017**, 35, 599-599	2.2	
212	Comprehensive genomic sequencing of urothelial tumors to identify rare driver genomic alterations in SMARCB1 in a subset of patients.. *Journal of Clinical Oncology*, **2017**, 35, 385-385	2.2	
211	Comprehensive genomic profiling of urethral cancer to reveal distinctive features compared to bladder cancer.. *Journal of Clinical Oncology*, **2017**, 35, 429-429	2.2	
210	Impact of age on genomic alterations associated with pancreatic ductal adenocarcinoma (PDAC).. *Journal of Clinical Oncology*, **2017**, 35, 282-282	2.2	
209	Association of tumor mutational burden in cutaneous squamous cell carcinoma with genomic alterations in Notch family receptors.. *Journal of Clinical Oncology*, **2017**, 35, e13031-e13031	2.2	

208	Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with pancreatic ductal adenocarcinoma (PDA).. *Journal of Clinical Oncology*, **2017**, 35, 4128-4128	2.2	
207	Occurrence of ALK fusions in cancers other than non-small cell lung cancer in a wide variety of tumor types and response to anti-ALK targeted therapy.. *Journal of Clinical Oncology*, **2017**, 35, 11595-11595	2.2	0
206	BRCA1/2 reversion mutations in pancreatobiliary cancer identified from patient biopsies.. *Journal of Clinical Oncology*, **2017**, 35, 4130-4130	2.2	
205	Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC).. *Journal of Clinical Oncology*, **2017**, 35, 1016-1016	2.2	1
204	Accelerating clinical trial enrollment with comprehensive genomic profiling (CGP) and just-in-time clinical trial sites: An index case of a paradigm shift.. *Journal of Clinical Oncology*, **2017**, 35, 6539-6539	2.2	
203	BRCA1/2 reversion mutations in prostate cancer identified from clinical tissue and liquid biopsy samples.. *Journal of Clinical Oncology*, **2017**, 35, 5024-5024	2.2	1
202	Clinical and genomic alterations features of patients with advanced colitis associated cancers (CAC).. *Journal of Clinical Oncology*, **2017**, 35, e15010-e15010	2.2	
201	Feasibility of collaborative precision medicine oncology between academic- and community-based hospitals.. *Journal of Clinical Oncology*, **2017**, 35, e18015-e18015	2.2	
200	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. *Molecular Cancer Therapeutics*, **2016**, 15, 2475-2485	6.1	49
199	Biliary cancer: Utility of next-generation sequencing for clinical management. *Cancer*, **2016**, 122, 3838-3847	6.4	185
198	Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. *Science Translational Medicine*, **2016**, 8, 334ra53	17.5	73
197	Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations. *Clinical Cancer Research*, **2016**, 22, 6061-6068	12.9	81
196	Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy. *Journal of Clinical Oncology*, **2016**, 34, e34-7	2.2	9
195	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. *Cancer Discovery*, **2016**, 6, 154-65	24.4	269
194	Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. *European Urology Focus*, **2016**, 2, 204-209	5.1	30
193	Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers. *Gynecologic Oncology*, **2016**, 141, 2-9	4.9	26
192	Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations. *Oncologist*, **2016**, 21, 33-9	5.7	55
191	Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. *European Urology*, **2016**, 70, 348-57	10.2	82

190	Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study. *Breast Cancer Research and Treatment*, **2016**, 155, 405-13	4.4	13
189	Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing. *Clinical Cancer Research*, **2016**, 22, 3281-5	12.9	22
188	Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. *European Urology*, **2016**, 70, 516-21	10.2	61
187	Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2016**, 34, e141-4	2.2	55
186	Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. *Journal of Clinical Pathology*, **2016**, 69, 403-8	3.9	40
185	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. *Clinical Cancer Research*, **2016**, 22, 1499-509	12.9	311
184	Clinical Relevant Alterations Identified By Comprehensive Genomic Profiling Can Potentially Improve Therapeutic Option and Change Prognosis in Hematologic Malignancies. *Blood*, **2016**, 128, 5109-5109	2.2	1
183	Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.. *Journal of Clinical Oncology*, **2016**, 34, 105-105	2.2	9
182	Assessment of tumor mutation burden from >60,000 clinical cancer patients using comprehensive genomic profiling.. *Journal of Clinical Oncology*, **2016**, 34, 11558-11558	2.2	8
181	Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP).. *Journal of Clinical Oncology*, **2016**, 34, 1523-1523	2.2	10
180	Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.. *Journal of Clinical Oncology*, **2016**, 34, 3587-3587	2.2	24
179	Comparison of upper tract urothelial carcinoma and urothelial carcinoma of the bladder to reveal key differences in mutational profile and load.. *Journal of Clinical Oncology*, **2016**, 34, 4522-4522	2.2	2
178	Comprehensive genomic profiling of neuroendocrine carcinoma of the prostate.. *Journal of Clinical Oncology*, **2016**, 34, 5027-5027	2.2	3
177	TMPRSS-ERG fusion in men with prostate cancer (PCa) and non-prostate malignancies: Defining a role for comprehensive genomic profiling (CGP) to guide clinical care.. *Journal of Clinical Oncology*, **2016**, 34, 5037-5037	2.2	1
176	Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.. *Journal of Clinical Oncology*, **2016**, 34, 9017-9017	2.2	108
175	Comprehensive genomic profiling of 298 lung cancers of varying histologies harboring MET exon 14 alterations.. *Journal of Clinical Oncology*, **2016**, 34, 9021-9021	2.2	0
174	MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers.. *Journal of Clinical Oncology*, **2016**, 34, 9068-9068	2.2	13
173	Deep sequencing of metastatic cutaneous basal cell and squamous cell carcinomas to reveal distinctive genomic profiles and new routes to targeted therapies.. *Journal of Clinical Oncology*, **2016**, 34, 9522-9522	2.2	2

172	Analysis of tumor mutation burden (TMB) in >51,000 clinical cancer patients to identify novel non-coding PMS2 promoter mutations associated with increased TMB.. *Journal of Clinical Oncology*, **2016**, 34, 9572-9572	2.2	4
171	Distinguishing head and neck cancer metastasis from second primary squamous lung cancer in the genomic era.. *Journal of Clinical Oncology*, **2016**, 34, e17506-e17506	2.2	1
170	Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors.. *Journal of Clinical Oncology*, **2016**, 34, e23049-e23049	2.2	2
169	Comparison of comprehensive genomic profiling (CGP) and hotspot next generation sequencing (NGS) assays in identifying treatment options for care of patients with metastatic cancer in in the community setting.. *Journal of Clinical Oncology*, **2016**, 34, e23120-e23120	2.2	2
168	Correlation between findings from comprehensive genomic profiling and targeted therapy response in metastatic renal cell carcinoma.. *Journal of Clinical Oncology*, **2016**, 34, 570-570	2.2	2
167	Evaluation of microsatellite instability (MSI) status in gastrointestinal (GI) tumor samples tested with comprehensive genomic profiling (CGP).. *Journal of Clinical Oncology*, **2016**, 34, 528-528	2.2	5
166	Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome. *PLoS Genetics*, **2016**, 12, e1006501	6	64
165	Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma. *Oncotarget*, **2016**, 7, 52442-52449	3.3	4
164	Comprehensive genomic profiling of renal cell carcinoma with sarcomatoid dedifferentiation to pinpoint recurrent genomic alterations.. *Journal of Clinical Oncology*, **2016**, 34, 537-537	2.2	
163	Latent class analysis of bladder urothelial carcinoma to reveal sub-classes defined by alterations to chromatin and signal transduction networks.. *Journal of Clinical Oncology*, **2016**, 34, 469-469	2.2	
162	Comprehensive genomic profiling of neuroendocrine carcinoma of the prostate.. *Journal of Clinical Oncology*, **2016**, 34, 187-187	2.2	
161	Characterization of mutational load in patients with advanced urothelial cancer.. *Journal of Clinical Oncology*, **2016**, 34, 460-460	2.2	
160	Comprehensive genomic profiling (CGP) of advanced nonseminomatous testicular germ cell tumors (NSGCT) to reveal clinically relevant genomic alterations (CRGA) to guide targeted therapy.. *Journal of Clinical Oncology*, **2016**, 34, 477-477	2.2	
159	Comprehensive genomic profiling of urothelial carcinoma of the kidney and ureter: Comparison with urothelial carcinoma of the bladder and impact on potential for targeted therapy selection.. *Journal of Clinical Oncology*, **2016**, 34, 371-371	2.2	
158	Comprehensive genomic profiling in colorectal cancer (CRC) to identify differing frequencies of clinically relevant genomic alterations (CRGA) in tumors of patients (pts) less than age 50 as compared to those of pts over age 65.. *Journal of Clinical Oncology*, **2016**, 34, 570-570	2.2	
157	Comprehensive genomic profiling (CGP) to assess mutational load in gastric and esophageal adenocarcinomas: Implications for immunotherapies.. *Journal of Clinical Oncology*, **2016**, 34, 66-66	2.2	0
156	Comprehensive genomic profiling of advanced colorectal carcinoma in the course of clinical care to identify KRAS insertions not detected by focused molecular testing.. *Journal of Clinical Oncology*, **2016**, 34, 497-497	2.2	
155	Biomarkers of immune checkpoint inhibitor response in metastatic breast cancer: PD-L1 protein expression, CD274 gene amplification, and total mutational burden.. *Journal of Clinical Oncology*, **2016**, 34, 3057-3057	2.2	1

154	Distinct age-associated genomic profiles in acute myeloid leukemia (AML) using FoundationOne heme.. *Journal of Clinical Oncology*, **2016**, 34, 7041-7041	2.2	1
153	Investigating the Utility of comprehensive genomic Profiling for patients with newly diagnosed breast cancer.. *Journal of Clinical Oncology*, **2016**, 34, TPS11617-TPS11617	2.2	
152	Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers.. *Journal of Clinical Oncology*, **2016**, 34, 9088-9088	2.2	
151	Correlation of genomic alterations with outcome in patients (pts) with urothelial carcinoma (UC).. *Journal of Clinical Oncology*, **2016**, 34, e16021-e16021	2.2	
150	Genomic landscape of urothelial cancer (UC), chemotherapy (CTX) response, and outcome based on smoking status.. *Journal of Clinical Oncology*, **2016**, 34, e16030-e16030	2.2	
149	Comprehensive genomic profiling to identify clinically relevant genomic alterations in patients with advanced penile cancers.. *Journal of Clinical Oncology*, **2016**, 34, 4573-4573	2.2	
148	Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA).. *Journal of Clinical Oncology*, **2016**, 34, 5591-5591	2.2	2
147	DNA-based genomic profiling for classification of tissue of origin for patients with carcinoma of unknown primary site.. *Journal of Clinical Oncology*, **2016**, 34, 11519-11519	2.2	
146	A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments. *Blood*, **2016**, 128, 117-117	2.2	1
145	High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1. *Blood*, **2016**, 128, 4416-4416	2.2	0
144	Comprehensive Clinical Genomic Profiling Defines Age-Associated Molecular Targets in Pediatric and Adult Acute Myeloid Leukemia. *Blood*, **2016**, 128, 596-596	2.2	
143	Real-Time Genomic Profiling Identifies Novel Mutations and Improved Therapy for Histiocytoses. *Blood*, **2016**, 128, 2723-2723	2.2	
142	Comprehensive Genomic Profiling for Improved Diagnosis and Therapy of Pediatric Acute Leukemias. *Blood*, **2016**, 128, 1605-1605	2.2	
141	Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. *Oncoscience*, **2016**, 3, 164-72	0.8	29
140	Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 1345-1350	7.3	18
139	Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. *Npj Genomic Medicine*, **2016**, 1,	6.2	74
138	Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 499-502	7.3	23
137	Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. *Oncologist*, **2016**, 21, 684-91	5.7	61

136	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. *Cancer Research*, **2016**, 76, 3690-701	10.1	154
135	Acquired ALK L1152R Mutation Confers Resistance to Ceritinib and Predicts Response to Alectinib. *Journal of Thoracic Oncology*, **2016**, 11, e87-8	8.9	21
134	BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. *Cancer Discovery*, **2016**, 6, 594-600	24.4	52
133	EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. *Cancer Discovery*, **2016**, 6, 601-11	24.4	65
132	Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. *Blood*, **2016**, 127, 3004-14	2.2	185
131	Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers. *Oncologist*, **2016**, 21, 1315-1325	5.7	49
130	Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. *Cancer Immunology Research*, **2016**, 4, 959-967	12.5	318
129	Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. *Journal of Thoracic Oncology*, **2016**, 11, 1493-502	8.9	177
128	The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. *International Journal of Cancer*, **2016**, 138, 881-90	7.5	168
127	Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. *Clinical Cancer Research*, **2015**, 21, 3631-9	12.9	183
126	Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling. *Lung Cancer*, **2015**, 88, 352-4	5.9	30
125	Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. *Oncologist*, **2015**, 20, 316-22	5.7	125
124	Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. *Lung Cancer*, **2015**, 89, 357-9	5.9	63
123	Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. *Cancer Discovery*, **2015**, 5, 860-77	24.4	476
122	Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles. *European Journal of Cancer*, **2015**, 51, 791-9	7.5	64
121	Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. *Lung Cancer*, **2015**, 89, 76-9	5.9	48
120	Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. *Clinical Lung Cancer*, **2015**, 16, e105-9	4.9	9
119	Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation. *European Urology*, **2015**, 67, 1195-1196	10.2	19

118	Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation. *European Urology*, **2015**, 68, 341-3	10.2	4
117	Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. *Breast Cancer Research and Treatment*, **2015**, 154, 155-62	4.4	57
116	RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors. *Cancer Discovery*, **2015**, 5, 1262-70	24.4	69
115	Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. *Oncologist*, **2015**, 20, 7-12	5.7	54
114	Identification of ANLN as ETV6 partner gene in recurrent t(7;12)(p15;p13): a possible role of deregulated ANLN expression in leukemogenesis. *Molecular Cancer*, **2015**, 14, 197	42.1	1
113	STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. *Journal of Hematology and Oncology*, **2015**, 8, 66	22.4	56
112	Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification. *Oncoscience*, **2015**, 2, 581-4	0.8	6
111	A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. *OncoTargets and Therapy*, **2015**, 8, 3561-4	4.4	6
110	Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. *Oncologist*, **2015**, 20, 1132-9	5.7	69
109	Genomic Profiling of Cancers of Unknown Primary Site--Reply. *JAMA Oncology*, **2015**, 1, 542-3	13.4	2
108	Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. *Clinical Cancer Research*, **2015**, 21, 1514-24	12.9	165
107	Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations. *Blood*, **2015**, 126, 369-369	2.2	1
106	Comprehensive Genomic Profiling (CGP) of Angioimmunoblastic T-Cell Lymphoma (AITL) to Prospectively Inform Diagnosis and Clinical Management. *Blood*, **2015**, 126, 3898-3898	2.2	1
105	Comprehensive genomic profiling (CGP) of advanced cancers to identify MET exon 14 alterations that confer sensitivity to MET inhibitors.. *Journal of Clinical Oncology*, **2015**, 33, 11007-11007	2.2	4
104	Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy.. *Journal of Clinical Oncology*, **2015**, 33, 11019-11019	2.2	5
103	Comprehensive genomic profiling of sarcomas from 267 adolescents and young adults to reveal a spectrum of targetable genomic alterations.. *Journal of Clinical Oncology*, **2015**, 33, 11020-11020	2.2	4
102	Germline variants in cancer risk genes detected by NGS-based comprehensive tumor genomic profiling (CGP).. *Journal of Clinical Oncology*, **2015**, 33, 11084-11084	2.2	3
101	Comprehensive genomic profiling of clinically advanced colorectal carcinoma to reveal frequent opportunities for targeted therapies.. *Journal of Clinical Oncology*, **2015**, 33, 3553-3553	2.2	5

100	Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations.. *Journal of Clinical Oncology*, **2015**, 33, 4009-4009	2.2	13
99	Comprehensive genomic profiling (CGP) of cervical squamous cell carcinoma (cSCC) to identifiy targeted therapy options.. *Journal of Clinical Oncology*, **2015**, 33, 5602-5602	2.2	1
98	Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations.. *Journal of Clinical Oncology*, **2015**, 33, 231-231	2.2	10
97	Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer.. *Journal of Clinical Oncology*, **2015**, 33, 320-320	2.2	4
96	Comprehensive genomic profiling of 443 cases of renal cell carcinoma to reveal frequent clinically relevant genomic alterations.. *Journal of Clinical Oncology*, **2015**, 33, 433-433	2.2	1
95	Comprehensive genomic profiling (CGP) of advanced stage esophageal squamous cell carcinomas (ESCC) and esophageal adenocarcinomas (EAC) to reveal similarities and differences.. *Journal of Clinical Oncology*, **2015**, 33, 7-7	2.2	
94	Comprehensive genomic profiling of anal squamous cell carcinoma to reveal frequency of clinically relevant genomic alterations in the PI3K/mTOR pathway.. *Journal of Clinical Oncology*, **2015**, 33, 3522-3522	2.2	
93	Comprehensive genomic profiling of primary intracranial malignant neoplasms to reveal frequency of clinically relevant genomic alterations.. *Journal of Clinical Oncology*, **2015**, 33, e13007-e13007	2.2	
92	Amplification of CRKL in human cancer: A rare event associated with potential sensitivity to targeted therapy.. *Journal of Clinical Oncology*, **2015**, 33, 1526-1526	2.2	
91	Comprehensive genomic profiling (CGP) of gynecologic malignancies in Israeli population to reveal potentially clinically relevant genomic alterations and opportunities for targeted therapies.. *Journal of Clinical Oncology*, **2015**, 33, e16578-e16578	2.2	
90	Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer.. *Journal of Clinical Oncology*, **2015**, 33, 4514-4514	2.2	
89	Genomic analysis of colitis-associated cancers.. *Journal of Clinical Oncology*, **2015**, 33, 3566-3566	2.2	
88	Comprehensive genomic profiling of 443 patients with advanced renal cell carcinoma (RCC) to reveal clinically relevant genomic alterations and to aid in classification of rare subtypes.. *Journal of Clinical Oncology*, **2015**, 33, 4520-4520	2.2	
87	Frequency of clinically relevant genomic alterations using comprehensive genomic profiling (CGP) for the management of advanced gynecologic malignancies in a community setting.. *Journal of Clinical Oncology*, **2015**, 33, e22068-e22068	2.2	
86	Utilization and clinical impact of genomic profiling for EGFR and ALK in non-squamous non-small cell lung cancer (NSCLC) in the community setting.. *Journal of Clinical Oncology*, **2015**, 33, e19113-e19113	2.2	
85	Intratumoral heterogeneity of cancer driver genomic alterations across several tumor types.. *Journal of Clinical Oncology*, **2015**, 33, 1558-1558	2.2	
84	Comprehensive genomic profiling of advanced stage esophageal squamous cell carcinomas (ESCC) and esophageal adenocarcinomas (EAC).. *Journal of Clinical Oncology*, **2015**, 33, 1535-1535	2.2	
83	Comprehensive genomic profiling identifies clinically relevant genomic alterations in relapsed and metastatic penile squamous cell carcinoma.. *Journal of Clinical Oncology*, **2015**, 33, e15628-e15628	2.2	

82	A U.S.-based prospective, multi-center, non-interventional study of the role of comprehensive genomic profiling in the clinic.. *Journal of Clinical Oncology*, **2015**, 33, e22183-e22183	2.2	
81	Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder to reveal frequency of clinically relevant genomic alterations.. *Journal of Clinical Oncology*, **2015**, 33, 4526-4526	2.2	
80	Comprehensive genomic profiling of salivary gland adenocarcinomas to reveal frequency of druggable targets.. *Journal of Clinical Oncology*, **2015**, 33, 6040-6040	2.2	
79	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. *Blood*, **2015**, 126, 481-481	2.2	
78	Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL. *Blood*, **2015**, 126, 1422-1422	2.2	
77	Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay. *Blood*, **2015**, 126, 2668-2668	2.2	
76	Predictive and Prognostic Significance of Comprehensive Genomic Profiling in Patients with Diffuse Large B-Cell Lymphoma. *Blood*, **2015**, 126, 2651-2651	2.2	
75	Emergence of constitutively active estrogen receptor-□mutations in pretreated advanced estrogen receptor-positive breast cancer. *Clinical Cancer Research*, **2014**, 20, 1757-1767	12.9	415
74	Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. *Clinical Breast Cancer*, **2014**, 14, e14-6	3	18
73	Genomics-based early-phase clinical trials in oncology: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. *European Journal of Cancer*, **2014**, 50, 2747-51	7.5	6
72	Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary. *Case Reports in Oncology*, **2014**, 7, 503-8	1	25
71	Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus. *Case Reports in Clinical Pathology*, **2014**, 1, 151-154	0.1	10
70	Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib. *Case Reports in Oncology*, **2014**, 7, 343-8	1	11
69	Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. *Nature Communications*, **2014**, 5, 3116	17.4	394
68	Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. *Journal of Clinical Oncology*, **2014**, 32, e88-91	2.2	38
67	Melanoma BRAF fusions--response. *Clinical Cancer Research*, **2014**, 20, 6632	12.9	3
66	Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. *Cancer Discovery*, **2014**, 4, 889-95	24.4	250
65	Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. *Clinical Cancer Research*, **2014**, 20, 6551-8	12.9	67

64	Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E5401-10	11.5	183
63	Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib. *Cancer Biology and Therapy*, **2014**, 15, 970-4	4.6	7
62	Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. *Cancer Discovery*, **2014**, 4, 1398-405	24.4	112
61	Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. *Modern Pathology*, **2014**, 27, 271-80	9.8	108
60	Patient Derived Xenograft (PDX) Models Recapitulate the Genomic-Driver Composition of Acute Leukemia Samples. *Blood*, **2014**, 124, 286-286	2.2	3
59	Novel Chromatin Modifying Gene Alterations and Significant Survival Association of ATM and P53 in Mantle Cell Lymphoma. *Blood*, **2014**, 124, 3033-3033	2.2	2
58	Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling. *Blood*, **2014**, 124, 3418-3418	2.2	3
57	Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma. *Blood*, **2014**, 124, 4775-4775	2.2	4
56	Clinical application of comprehensive next-generation sequencing-based genomic profiling for identification of actionable genomic alterations in pediatric solid tumors and hematolymphoid malignancies: The Foundation Medicine pediatric experience.. *Journal of Clinical Oncology*, **2014**, 32, 10035-10035	2.2	1
55	Whole-exome and targeted sequencing of angiosarcomas: Target identification and treatment implications.. *Journal of Clinical Oncology*, **2014**, 32, 10512-10512	2.2	1
54	Comprehensive genomic profiling of solid tumors from 677 adolescents and young adults for revealing a distinct spectrum of targetable genomic alterations.. *Journal of Clinical Oncology*, **2014**, 32, 11008-11008	2.2	2
53	Targeted next-generation sequencing (NGS) of carcinoma of unknown primary site (CUP): Actionable genomic alterations (GA) and new routes to targeted therapies.. *Journal of Clinical Oncology*, **2014**, 32, 11048-11048	2.2	1
52	Next-generation sequencing to identify molecular alterations in DNA repair and chromatin maintenance genes associated with pathologic complete response (pT0) to neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) in muscle-invasive bladder cancer (MIBC).. *Journal of Clinical Oncology*, **2014**, 32, 4538-4538	2.2	1
51	BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2014**, 32, 8042-8042	2.2	1
50	Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma.. *Journal of Clinical Oncology*, **2014**, 32, 8049-8049	2.2	9
49	Targeted treatment of RAI-resistant metastatic thyroid cancer postcomprehensive genomic profiling.. *Journal of Clinical Oncology*, **2014**, 32, e22070-e22070	2.2	1
48	Genomic profiling and precision medicine in 3,745 patients with advanced cancer.. *Journal of Clinical Oncology*, **2014**, 32, e13521-e13521	2.2	
47	PI3K/AKT/mTOR genomic alterations in 94 patients with metastatic breast cancer in the phase I clinic at MD Anderson: Prevalence and association with response.. *Journal of Clinical Oncology*, **2014**, 32, 2606-2606	2.2	

46	Next-generation sequencing (NGS) in relapsed/refractory triple-negative breast cancer (TNBC) in Israel.. *Journal of Clinical Oncology*, **2014**, 32, 1028-1028	2.2	
45	Landscape of genomic alterations (GA) detected by next-generation sequencing (NGS) in non-small cell lung cancer (NSCLC) adenocarcinoma in Israel.. *Journal of Clinical Oncology*, **2014**, 32, e19111-e19111	2.2	
44	Rictor amplification to define a novel and unique subset of lung cancer patients.. *Journal of Clinical Oncology*, **2014**, 32, 8027-8027	2.2	
43	Next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in pan-negative lung adenocarcinomas (ADC) from patients with no smoking or a light smoking (NS/LS) history.. *Journal of Clinical Oncology*, **2014**, 32, 8029-8029	2.2	
42	Therapeutic insights for malignant phyllodes from next-generation sequencing.. *Journal of Clinical Oncology*, **2014**, 32, e22069-e22069	2.2	
41	Next-generation sequencing (NGS)-based profiling of pancreatic acinar cell carcinoma for identification of a recurrent SND1-BRAF fusion.. *Journal of Clinical Oncology*, **2014**, 32, 11029-11029	2.2	
40	Next-generation sequencing (NGS) in metastatic colorectal cancer (CRC) patients (pts) in Israel.. *Journal of Clinical Oncology*, **2014**, 32, e14548-e14548	2.2	
39	Unique pattern of metastasis to the adenexa in ALK rearranged non-small cell lung cancer.. *Journal of Clinical Oncology*, **2014**, 32, e19036-e19036	2.2	
38	Genomic Analysis of Serial Samples from CLL Patients Identifies Clonal Events Associated with Disease Progression. *Blood*, **2014**, 124, 1954-1954	2.2	
37	A Comprehensive Clinical Next Generation Sequencing-Based Assay Can Impact Hematopathologic Diagnosis in a Significant Subset of Patients with Hematologic Malignancies. *Blood*, **2014**, 124, 2984-2984	2.2	
36	Clinical Utility of Comprehensive Profiling of Genomic Alterations in Hematologic Malignancies. *Blood*, **2014**, 124, 1072-1072	2.2	
35	Genomic Alterations of Histone Modification Genes Are Significantly Less Common in Non-Hodgkin Lymphomas of Adolescents and Young Adults Compared to Older Patients. *Blood*, **2014**, 124, 1684-1684	2.2	
34	Identification of Actionable Genomic Alterations Across Different Lymphoma Histologies Using a Comprehensive Next Generation Genomic Sequencing Clinical Assay. *Blood*, **2014**, 124, 3000-3000	2.2	
33	Utility of Combined DNA and RNA Next Generation Sequencing in Leukemias for Identification of Prognostic and Therapeutically Relevant Genomic Alterations in Clinical Practice. *Blood*, **2014**, 124, 1039-1039	2.2	
32	Comprehensive Hybrid Capture-Based Genomic Profiling of T-Cell Leukemias and Lymphomas Reveals Targetable JAK1 and JAK3 Co-Existing Mutations. *Blood*, **2014**, 124, 1672-1672	2.2	
31	Genomic Profiling Combining DNA and RNA Analysis of 112 Formalin-Fixed Paraffin-Embedded Diffuse Large B Cell Lymphoma Specimens Identifies a High Frequency of Clinically Relevant Genomic Alterations. *Blood*, **2014**, 124, 704-704	2.2	
30	Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. *Nature Biotechnology*, **2013**, 31, 1023-31	44.5	1353
29	Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. *Genome Medicine*, **2013**, 5, 49	14.4	158

28	BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. *Clinical Cancer Research*, **2013**, 19, 6696-702	12.9	122
27	Patient Derived Xenograft (PDX) Models Faithfully Recapitulate The Genetic Composition Of Primary AML. *Blood*, **2013**, 122, 1328-1328	2.2	1
26	Integrated Genetic Profiling Of JAK2 Wildtype Chronic-Phase Myeloproliferative Neoplasms. *Blood*, **2013**, 122, 1588-1588	2.2	1
25	Profiling Genomic Alterations Of Diffuse Large B-Cell Lymphoma (DLBCL) At Diagnosis, Relapse, and Transformation, Using a Novel Clinical Diagnostic Targeted Sequencing Platform. *Blood*, **2013**, 122, 1761-1761	2.2	1
24	Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay. *Blood*, **2013**, 122, 230-230	2.2	2
23	Extensive High-Depth Sequencing Of Longitudinal CLL Samples Identifies Frequent Mutations In MAP Kinase Signaling and Novel Mutations Activating Notch and Beta-Catenin. *Blood*, **2013**, 122, 2858-2858	2.2	2
22	Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma. *Blood*, **2013**, 122, 755-755	2.2	1
21	Potentially actionable kinase fusions in inflammatory myofibroblastic tumors.. *Journal of Clinical Oncology*, **2013**, 31, 10513-10513	2.2	3
20	An analysis of ERBB2 alterations (amplifications and mutations) found by next-generation sequencing (NGS) in 2000+ consecutive solid tumor (ST) patients.. *Journal of Clinical Oncology*, **2013**, 31, 11000-11000	2.2	1
19	Use of next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in diverse solid tumor types: The Foundation Medicine (FMI) experience with 2,200+ clinical samples.. *Journal of Clinical Oncology*, **2013**, 31, 11020-11020	2.2	2
18	Frequency of MET amplification determined by comprehensive next-generation sequencing (NGS) in multiple solid tumors and implications for use of MET inhibitors.. *Journal of Clinical Oncology*, **2013**, 31, 11068-11068	2.2	6
17	Clinical next generation sequencing (NGS) to reveal high frequency of alterations to guide targeted therapy in lung cancer patients.. *Journal of Clinical Oncology*, **2013**, 31, 8020-8020	2.2	3
16	NTRK1 gene fusions as a novel oncogene target in lung cancer.. *Journal of Clinical Oncology*, **2013**, 31, 8023-8023	2.2	9
15	A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs).. *Journal of Clinical Oncology*, **2013**, 31, 8036-8036	2.2	10
14	Next-generation sequencing of genomic and cDNA to identify a high frequency of kinase fusions involving ROS1, ALK, RET, NTRK1, and BRAF in Spitz tumors.. *Journal of Clinical Oncology*, **2013**, 31, 9002-9002	2.2	2
13	Frequent LOH of CYP2D6 in ER+ breast cancer determined by next-generation sequencing (NGS).. *Journal of Clinical Oncology*, **2013**, 31, 534-534	2.2	
12	Use of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer.. *Journal of Clinical Oncology*, **2013**, 31, 1009-1009	2.2	3
11	Clinical next generation sequencing (NGS) of fine needle aspiration (FNA) biopsies in non-small cell lung (NSCLC) and pancreatic cancers.. *Journal of Clinical Oncology*, **2013**, 31, 11100-11100	2.2	0

10	An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2013**, 31, 8039-8039	2.2	
9	Overview Of The Genomic Landscape Of High Risk Diffuse Large B-Cell Lymphoma Using Targeted DNA and RNA Sequencing. *Blood*, **2013**, 122, 501-501	2.2	
8	Mutational Profiling Of Myeloid Malignancies For Prediction Of Disease Relapse Following Allogeneic Stem Cell Transplantation. *Blood*, **2013**, 122, 2096-2096	2.2	
7	Comprehensive Mutational Profiling In Myelodysplastic Syndromes Treated With Decitabine and Tretinoin. *Blood*, **2013**, 122, 2791-2791	2.2	
6	High-Throughput Mutational Profiling Of Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia Reveals Frequent Mutations In NRAS In JAK2V617F-Negative Post-MPN AML. *Blood*, **2013**, 122, 4098-4098	2.2	
5	Next-generation sequencing (NGS) to identify actionable genomic changes in common and rare solid tumors: The FMI experience with the initial 50 consecutive patients.. *Journal of Clinical Oncology*, **2012**, 30, 10590-10590	2.2	2
4	Use of next-generation sequencing (NGS) to detect a novel ALK fusion and a high frequency of other actionable alterations in colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2012**, 30, 3533-3533	2.2	1
3	Frequency of actionable genomic alterations in early-stage lung adenocarcinoma (LA) detected by next-generation sequencing (NGS).. *Journal of Clinical Oncology*, **2012**, 30, e17541-e17541	2.2	
2	Concordance of driver mutations in primary and matched metastasis from patients with non-small cell lung cancer (NSCLC) using next-generation sequencing (NGS).. *Journal of Clinical Oncology*, **2012**, 30, 7529-7529	2.2	
1	EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 13306-11	11.5	3659